Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Chlorambucil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.52 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.52 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.52 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.97 |
| ▸ | THPO | P40225 | 2/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.97 |
| ▸ | GMNN | O75496 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.97 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.97 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorambucil SCHEMBL4308 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL5318105 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL28426894 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL27861200 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL28290938 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL23753952 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL11252839 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL28447772 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL5846926 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT | |
| Chlorambucil SCHEMBL28081945 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1HIF1ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097823-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF MUSTARDS AND MUSTARD-RELATED COMPOUNDS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-03-30 | — | — | US | disclosed |
| EP-2077991-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF MUSTARDS AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES | Techfields Biochem Co. Ltd (CN) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008041059-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF MUSTARDS AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES | TECHFIELDS BIOCHEM CO. LTD (CN) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097823-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF MUSTARDS AND MUSTARD-RELATED COMPOUNDS | HPD, NOTUM, HASPIN | SLC6A3 389/4885CHRM2 1856/4885ADRA2A 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.